PR Newswire
CORAL GABLES, Fla., Nov. 11, 2021
CORAL GABLES, Fla., Nov. 11, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced financial results for the three and nine months ended September 30, 2021.
"Our REL-1017 development program for the treatment of major depressive disorder remains on track, and we expect key data catalysts in each quarter of next year," said Dr. Sergio Traversa, Relmada's Chief Executive Officer. "We anticipate top-line results from our second human abuse potential study, this one assessing REL-1017 versus intravenous ketamine, in the first quarter, followed by top-line data from RELIANCE III, our ongoing monotherapy registrational Phase 3 study in the second quarter. We expect top-line results from RELIANCE I and RELIANCE II, our Phase 3 pivotal studies for adjunctive treatment, in the third and fourth quarters of 2022, respectively. Importantly, our robust R&D initiatives are supported by a strong balance sheet."
Recent Corporate Highlights
Third Quarter 2021 Financial Results
Nine Months Ended September 30, 2021 Financial Results
Conference Call and Webcast Details | ||
Date: | Thursday, November 11 | |
Time: | 4:30pm Eastern Time | |
Toll Free: | 855-407-0792 | |
International: | 201-689-8263 | |
Conference ID: | 13724499 | |
Webcast: | https://78449.themediaframe.com/dataconf/productusers/vvdb/mediaframe/47253/indexl.html |
About REL-1017
REL-1017, a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, is currently in late-stage development for the treatment of MDD. The ongoing RELIANCE Clinical Research Program is designed to evaluate the potential for REL-1017 as a rapid-acting, oral, once-daily antidepressant treatment. In a Phase 2 trial, REL-1017 demonstrated robust, rapid, and sustained antidepressant effects with statistically significant improvements compared to placebo. The Phase 2 study also showed a favorable pharmacokinetic, safety, and tolerability profile of REL-1017 consistent with results observed in previously completed Phase 1 studies.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Our experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada' s lead program, REL-1017, is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as an adjunctive treatment and monotherapy treatment for MDD in adults. In addition, Relmada is advancing a clinical-stage program in neurodegenerative diseases based on psilocybin and select derivative molecules. Learn more at www.relmada.com.
Forward-Looking Statements
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to," "potential," "promising," and similar expressions. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including the risk factors described under the heading "Risk Factors" set forth in the Company's reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be a complete list.
Investor Contact:
Tim McCarthy
LifeSci Advisors
917-679-9282
[email protected]
Media Inquiries:
FischTank PR
[email protected]
Relmada Therapeutics, Inc. | ||||||||
Condensed Consolidated Balance Sheets | ||||||||
As of | ||||||||
September 30, | As of | |||||||
2021 (Unaudited) | December 31, 2020 | |||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 11,449,294 | $ | 2,495,397 | ||||
Short-term investments | 76,637,802 | 114,595,525 | ||||||
Lease payments receivable – short term | 84,592 | 79,457 | ||||||
Prepaid expenses | 2,715,478 | 903,190 | ||||||
Total current assets | 90,887,166 | 118,073,569 | ||||||
Fixed assets, net of accumulated depreciation | - | 1,258 | ||||||
Other assets | 25,000 | 25,000 | ||||||
Lease payments receivable – long term | 22,275 | 86,377 | ||||||
Total assets | $ | 90,934,441 | $ | 118,186,204 | ||||
Liabilities and Stockholders' Equity | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 12,708,546 | $ | 8,346,475 | ||||
Accrued expenses | 5,538,804 | 4,256,983 | ||||||
Total current liabilities | 18,247,350 | 12,603,458 | ||||||
Stockholders' Equity: | ||||||||
Preferred stock, $0.001 par value, 200,000,000 shares authorized, none issued and outstanding | - | - | ||||||
Class A convertible preferred stock, $0.001 par value, 3,500,000 shares authorized, none issued and outstanding | - | - | ||||||
Common stock, $0.001 par value, 50,000,000 shares authorized, 17,501,554 and 16,332,939 shares issued and outstanding, respectively | 17,502 | 16,333 | ||||||
Additional paid-in capital | 343,358,208 | 284,881,716 | ||||||
Accumulated deficit | (270,688,619) | (179,315,303) | ||||||
Total stockholders' equity | 72,687,091 | 105,582,746 | ||||||
Total liabilities and stockholders' equity | $ | 90,934,441 | $ | 118,186,204 |
Relmada Therapeutics, Inc. | ||||||||||||||||
Condensed Consolidated Statements of Operations | ||||||||||||||||
(Unaudited) | ||||||||||||||||
Three months ended | Nine months ended | |||||||||||||||
September 30, | September 30, | |||||||||||||||
2021 | 2020 | 2021 | 2020 | |||||||||||||
Operating expenses: | ||||||||||||||||
Research and development | $ | 33,993,974 | $ | 11,237,186 | $ | 65,347,708 | $ | 21,068,923 | ||||||||
General and administrative | 8,659,661 | 5,946,396 | 26,173,010 | 18,846,299 | ||||||||||||
Total operating expenses | 42,653,635 | 17,183,582 | 91,520,718 | 39,915,222 | ||||||||||||
Loss from operations | (42,653,635) | (17,183,582) | (91,520,718) | (39,915,222) | ||||||||||||
Other (expenses) income: | ||||||||||||||||
Interest/investment income, net | 297,648 | 363,300 | 1,040,429 | 1,174,957 | ||||||||||||
Realized loss on short-term investments | (336,949) | (86,171) | (513,328) | (244,972) | ||||||||||||
Unrealized gain (loss) on short-term investments | 86,745 | 3,946 | (379,699) | 290,973 | ||||||||||||
Total other income - net | 47,444 | 281,075 | 147,402 | 1,220,958 | ||||||||||||
Net loss | $ | (42,606,191) | $ | (16,902,507) | $ | (91,373,316) | $ | (38,694,264) | ||||||||
Loss per common share – basic and diluted | $ | (2.44) | $ | (1.05) | $ | (5.36) | $ | (2.52) | ||||||||
Weighted average number of common shares outstanding – basic and diluted | 17,478,477 | 16,044,670 | 17,038,583 | 15,371,118 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/relmada-therapeutics-provides-corporate-update-and-reports-third-quarter-2021-financial-results-301422499.html
SOURCE Relmada Therapeutics, Inc.
We use cookies to tailor your experience, measure site performance and present relevant offers and advertisements. By clicking ‘Accept’ or any content on this site, you agree that cookies can be placed on your browser. You can view our privacy policy to learn more.
If you would like to get more data, alerts and access to Real Vision videos, join us as an Insider Tracking Advantage Ultra member